Xavier Sanz

Dr. Xavier Sanz

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
XSXavier Sanz
Xavier Sanz
MZMin Zhao
Min Zhao
NRNuria Rodríguez
Nuria Rodríguez
RGRaquel Granado
Raquel Granado
PFPalmira Foro
Palmira Foro
MAManuel Algara
Manuel Algara
Purpose. Radiation therapy is a key treatment of breast cancer. Elderly patients with associated diseases that modify their performance status do not tolerate long periods of daily irradiation. The objective of this study is to analyze the results of weekly hypofractionated treatment in these patients. Material and Methods. Between 1992 and 2016, we included 486 elderly patients presenting concomitant pathology or sociofamilial problems in which it was not feasible to propose conventional treatment. They were treated with conservative surgery or mastectomy and then adjuvant hypofractionated irradiation, administering 5 Gy or 6.25 Gy in 6 fractions, once a week (total dose 30–37.5 Gy) over 6 weeks. Results. Breast cancer overall survival according to the Kaplan-Meier method at 5 years was 74.2%±2.3%; breast cancer disease-free survival was 90%±1.6%; local relapse-free survival was 96.5%±1% showing that patients die more from other causes and not from their neoplasia. Acute dermatitis was mild (75.6% of the patients grades I–III) and 30.6% had moderate chronic fibrosis. Conclusions. The once-weekly hypofractionated radiotherapy is a feasible and convenient option for elderly patients with breast cancer. It is a safe treatment modality with similar survival and local control results compared to standard fractionation, while the side effects are acceptable.

20 April 2021 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
XLX. Li
X. Li
XSXavier Sanz
Xavier Sanz
PFP. Foro
P. Foro
AMA. Martínez
A. Martínez
MZM. Zhao
M. Zhao
NRN. Rodríguez
N. Rodríguez

18 November 2021 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
YHY. Huang
Y. Huang
XSXavier Sanz
Xavier Sanz
NRN. Rodríguez
N. Rodríguez
XDX. Duran
X. Duran
AMA. Martínez
A. Martínez
MAM. Algara
M. Algara
Purpose: Radiation-induced toxicity (RIT) is usually assessed by inspection and palpation. Due to their subjective and unquantitative nature, objective methods are required. This study aimed to determine whether a quantitative tool is able to assess RIT and establish an underlying BED-response relationship in breast cancer. Methods: Patients following seven different breast radiation protocols were recruited to this study for RIT assessment with qualitative and quantitative examination. The biologically equivalent dose (BED) was used to directly compare different radiation regimens. RIT was subjectively evaluated by physicians using the Radiation Therapy Oncology Group (RTOG) late toxicity scores. Simultaneously an objective multiprobe device was also used to quantitatively assess late RIT in terms of erythema, hyperpigmentation, elasticity and skin hydration. Results: In 194 patients, in terms of the objective measurements, treated breasts showed higher erythema and hyperpigmentation and lower elasticity and hydration than untreated breasts (p < 0.001, p < 0.001, p < 0.001, p = 0.019, respectively). As the BED increased, Δerythema and Δpigmentation gradually increased as well (p = 0.006 and p = 0.002, respectively). Regarding the clinical assessment, the increase in BED resulted in a higher RTOG toxicity grade (p < 0.001). Quantitative assessments were consistent with RTOG scores. As the RTOG toxicity grade increased, the erythema and pigmentation values increased, and the elasticity index decreased (p < 0.001, p = 0.016, p = 0.005, respectively). Conclusions: The multiprobe device can be a sensitive and simple tool for research purpose and quantitatively assessing RIT in patients undergoing radiotherapy for breast cancer. Physician-assessed toxicity scores and objective measurements revealed that the BED was positively associated with the severity of RIT.

21 September 2016 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
XSXavier Sanz
Xavier Sanz
NDNURIA RODRIGUEZ DE DIOS
NURIA RODRIGUEZ DE DIOS
PFP. Foro
P. Foro
JDJ. Dengra
J. Dengra
ARA. Reig
A. Reig
MAM. Algara
M. Algara

8 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
XSXavier Sanz
Xavier Sanz
AEArantxa Eraso
Arantxa Eraso
RIReyes Ibáñez
Reyes Ibáñez
Rachel Aurora WilliamsRachel Aurora Williams
Rachel Aurora Williams
MAManuel Algara
Manuel Algara
Conservative surgery is the preferred treatment in the management of breast cancer followed by adjuvant whole-breast irradiation. Since the tumor bed is the main site of relapse, boost doses are conveniently administered according to risk factors for local relapse to increase the efficacy of the treatment. The benefit of a radiation boost is well established and it can be performed by several techniques like brachytherapy, external radiation or intraoperative radiotherapy. Greater precision in localizing the tumor cavity, immediacy and increased biological response are the main advantages of intraoperative boost irradiation. This modality of treatment can be performed by means of mobile electron accelerators or low-photon X-ray devices. There is a lot of research and some published series analyzing the results of the use of an intraoperative boost as an adjuvant treatment, after neoadjuvant systemic therapy and in combination with some reconstructive surgeries. This review discusses advantages of intraoperative radiotherapy and presents the main results of a boost in terms of local control, survival, tolerance and cosmesis.

21 February 2022 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
AEArantxa Eraso
Arantxa Eraso
XSXavier Sanz
Xavier Sanz
MMMeritxell Mollà
Meritxell Mollà
VRVicky Reyes
Vicky Reyes
APAgustí Pedro
Agustí Pedro
MAManuel Algara
Manuel Algara
Introduction: Daily, moderate hypofractionation has become standard treatment for breast cancer following breast-conserving surgery, although substantial variation exists in its use. This paper describes the generation of consensus-based recommendations for the utilisation of this therapy at the healthcare system level and compares these to American Society for Radiation Oncology (ASTRO) guidelines. Materials and methods: Consensus-based guidelines were developed in three steps, including a systematic literature review and involvement of radiation oncologists specialising in breast cancer in Catalonia: (a) creation of a working group and evidence review; (b) consideration of the levels of evidence and agreement on the formulation of survey questions; and (c) performance of survey and development of consensus-based recommendations. Results were compared to the ASTRO recommendations. Results: Consensus was above 80% for 10 of the 14 survey items. Experts supported hypofractionated radiotherapy for all breast cancer patients aged 40 years or more; with invasive carcinoma and breast-conserving surgery; without radiation of lymph nodes; and regardless of the tumour size, histological grade, molecular subtype, breast size, laterality, other treatment characteristics, or need for a boost. Over half favoured its use in all situations, even where available scientific evidence is insufficient. The resulting recommendations and the quality of the evidence are comparable to those from ASTRO, despite some differences in the degree of consensus. Conclusion: Specialists agree that hypofractionation is the standard treatment for breast cancer following breast-conserving surgery, but some specific areas require a higher level of evidence before unequivocally extending indications.